// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Disinhibition of spinal cord pain pathways underlies neuropathic pain hypersensitivity in rodents of both sexes

J. Mappleback - American Pain Society (APS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

Slow-K

7-year longitudinal trajectories of pain intensity in women with vulvodynia: contributions of treatment, pain characteristics, and psychosocial factors

M. Paquet - American Pain Society (APS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Does anxiety and depressive symptoms are associated with pain and its consequences? a daily diary study among couples coping with vulvodynia

M. Paquet - American Pain Society (APS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

CADD-35. THE DEVELOPMENT OF PERSONALIZED CAM AVATAR MODEL TO PREDICT CHEMOTHERAPEUTIC DRUG SENSITIVITY/RESISTANCE OF GLIOMAS

Martine Charbonneau - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Methadone hydrochloride

CADD-49. IDENTIFICATION AND VALIDATION OF AZOLES AS HK2 INHIBITORS IN GLIOBLASTOMA IN VITRO AND IN VIVO

Eric Xueyu Chen - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Posaconazole

ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

L Sue Frederick - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Pembrolizumab

ACTR-66. BEVACIZUMAB THERAPY FOR THE TREATMENT OF ADULT GLIOBLASTOMA: SYSTEMATIC REVIEW & META-ANALYSIS

Nagham Kaka - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Bevacizumab

ACTR-71. PHASE 1/2 STUDY OF DIANHYDROGALACTITOL (VAL-083) WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA

Zhong-ping Chen - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dianhydrogalactitol

TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY

Annie Mak - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Temozolomide

TMOD-35. CAN RARE SOX9-POSITIVE CELLS INCITE MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE?

Rebecca M Hill - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

TMOD-08. GROWTH IMPAIRMENT UNDER CONDITIONS FAVORING MITOCHONDRIAL OXIDATIVE METABOLISM IN A YEAST MODEL OF CANCER-ASSOCIATED ISOCITRATE DEHYDROGENASE MUTATION

Sophie Fiola - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

TMOD-02. DIFFUSE GLIOMATOSIS IN MOUSE MODEL OF GFAP TISSUE SPECIFIC KNOCK IN OF EGFRvIII AND KNOCK OUT OF p19 ARF

Gelareh Zadeh - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

EGFRvIII

TMOD-24. PATIENT-DERIVED BRAIN TUMOUR IPSCS: MODELS FOR INVESTIGATING GLIOMA STEMNESS AND DRUG DISCOVERY

Christian Smith - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Methadone hydrochloride

TMIC-17. IMMUNE MICROENVIRONMENT OF NF2-ALTERED RADIATION-INDUCED MENINGIOMAS

Suganth Suppiah - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

TMIC-07. HYPOXIC MICROENVIRONMENT CONFERS SPECIFIC ALTERATIONS IN DNA METHYLATION PROFILES IN GLIOBLASTOMA

Kenneth Aldape - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pimonidazole

SURG-09. AWAKE CRANIOTOMY FOR BRAIN TUMOR IN OCTOGENARIANS AND NONAGENARIANS

John Sinclair - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Remifentanil

STEM-14. GROWTH FACTOR RECEPTOR CO-INHERITANCE DURING ASYMMETRIC CELL DIVISION DRIVES THE CANCER STEM CELL PHENOTYPE

Vid Yogeswaran - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Martin van den Bent - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Temozolomide

RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS

David Shultz - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

RTHP-30. MANAGEMENT OF GLIOBLASTOMA IN THE ELDERLY - A 10-YEAR ANALYSIS OF THE BC CANCER AGENCY POPULATION

Jonathan Zeng - Society for Neuro-Oncology (SNO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved